Real-world data on tolerability of COVID-19 vaccination in patients with rheumatoid arthritis based on patient-reported outcomes.

ABSTRACT:

Objectives

To assess tolerability of COVID-19 vaccination in patients with RA and controls based on patient-reported outcomes (PROs).

Methods

In total, 266 study participants were included at 6 ± 1 weeks after their second vaccination (BioNTech/Pfizer (72.2%), AstraZeneca (18.8%) and Moderna (9.0%)). In a cross-sectional, observational study design, PRO data were recorded regarding both total and symptom-level tolerability.

Results

Overall tolerability was very high according to the patients' self-assessment scores (1.71 for the first and 1.72 for the second vaccination, 6-point Likert scale [1 (very good) to 6 (very poor)]) and did not differ significantly between patients with RA (n = 204) and controls (n = 62). Self-rated overall tolerability regardin

SUBMITTER: Feuchtenberger M 

PROVIDER: S-EPMC11398971 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature